Anee Soom*
Autoimmune neuromuscular disorders encompass a diverse group of conditions that affect the peripheral nervous system and muscles. Early and accurate diagnosis of these disorders is often challenging, necessitating the exploration of contemporary approaches to biomarkers for improved clinical management. This review examines the landscape of biomarkers in autoimmune neuromuscular diseases, encompassing conditions such as myasthenia gravis, Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. The review delves into the role of molecular, genetic and immunological biomarkers in disease diagnosis, prognosis and therapeutic monitoring. By scrutinizing the latest advancements and their potential applications, we underscore the significance of contemporary biomarker strategies in advancing our understanding and management of autoimmune neuromuscular disorders.
この記事をシェアする
English 
Spanish 
Chinese 
Russian 
German 
French 
Portuguese 
Hindi 